Brown Gibbons Lang & Company, a middle market investment bank, announced the acquisition of United States Drug Testing Laboratories Inc. (USDTL) by Northlane Capital Partners (NCP).
USDTL provides substance abuse toxicology services worldwide for healthcare facilities, child protection agencies, the Department of Defense, legal services, research, businesses and analytical/forensic laboratories. USDTL has more than 160 employees serving more than 1,000 customers in the United States and internationally.
Founded in 2003, NCP manages a $1 billion private equity fund investing in control buyouts of middle market companies based in North America. It looks for platform investments ranging in size from $5 million to $30 million of EBITDA. The firm is based in Bethesda, Maryland.
The new partnership will allow NCP to bring its experience in lab services to USDTL’s existing suite of forensic tests. This is also NCP’s first acquisition of 2025. Terms were not disclosed.
According to data in the LevinPro HC database, this transaction represents the fourth Laboratories, MRI and Dialysis acquisition of 2025. In 2024, 120 Laboratories, MRI and Dialysis transactions were reported.
